26 Sep 2023 , 01:01 AM
On September 26, after receiving an Establishment Inspection Report (EIR) from the US FDA (US Food and Drug Administration) for its Pashamylaram facility in Hyderabad, Gland Pharma’s shares regained some of their early losses and increased by as much as 2%.
The inspection took place between June 15 and June 27, 2023. The conclusion of an inspection is noted in the EIR report.
In the case of Gland Pharma, the inspection was conducted in order to pre-approve seven goods and determine whether the business was following the FDA’s good manufacturing practices.
Following the exchange filing, shares of Gland Pharma were trading higher on the NSE at 11.26 a.m., up 1.81% to Rs 1690.
For the first quarter that ended June 30, 2023, Gland Pharma Ltd. reported a 15.3% year-over-year (YoY) decline in net profit at Rs 194.1 crore.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
